Morgan Stanley’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-1,736,277
| Closed | -$35M | – | 8334 |
|
|
2021
Q3 | $35M | Buy |
1,736,277
+624,188
| +56% | +$17.2M | ﹤0.01% | 1557 |
|
|
2021
Q2 | $41.5M | Buy |
1,112,089
+255,479
| +30% | +$7.83M | 0.01% | 1463 |
|
|
2021
Q1 | $21.9M | Buy |
856,610
+801,509
| +1,455% | +$20.5M | ﹤0.01% | 1823 |
|
|
2020
Q4 | $1.21M | Buy |
55,101
+43,736
| +385% | +$963K | ﹤0.01% | 4548 |
|
|
2020
Q3 | $205K | Sell |
11,365
-21,419
| -65% | -$443K | ﹤0.01% | 5106 |
|
|
2020
Q2 | $833K | Buy |
32,784
+3,893
| +13% | +$83.9K | ﹤0.01% | 4302 |
|
|
2020
Q1 | $531K | Sell |
28,891
-122,944
| -81% | -$2.39M | ﹤0.01% | 4336 |
|
|
2019
Q4 | $3.35M | Buy |
151,835
+132,568
| +688% | +$2.67M | ﹤0.01% | 3614 |
|
|
2019
Q3 | $276K | Sell |
19,267
-6,064
| -24% | -$86.7K | ﹤0.01% | 4970 |
|
|
2019
Q2 | $399K | Buy |
25,331
+5,149
| +26% | +$70K | ﹤0.01% | 4721 |
|
|
2019
Q1 | $295K | Sell |
20,182
-72,822
| -78% | -$837K | ﹤0.01% | 4855 |
|
|
2018
Q4 | $995K | Buy |
93,004
+14,989
| +19% | +$197K | ﹤0.01% | 4280 |
|
|
2018
Q3 | $1.19M | Sell |
78,015
-20,857
| -21% | -$304K | ﹤0.01% | 4403 |
|
|
2018
Q2 | $1.21M | Buy |
98,872
+84,510
| +588% | +$1.06M | ﹤0.01% | 4487 |
|
|
2018
Q1 | $137K | Buy |
14,362
+12,488
| +666% | +$135K | ﹤0.01% | 5621 |
|
|
2017
Q4 | $17K | Buy |
1,874
+685
| +58% | +$5.04K | ﹤0.01% | 6122 |
|
|
2017
Q3 | $7K | Sell |
1,189
-57
| -5% | -$207 | ﹤0.01% | 6245 |
|
|
2017
Q2 | $4K | Sell |
1,246
-24,523
| -95% | -$77.4K | ﹤0.01% | 6392 |
|
|
2017
Q1 | $88K | Sell |
25,769
-10,975
| -30% | -$30.9K | ﹤0.01% | 5646 |
|
|
2016
Q4 | $106K | Sell |
36,744
-440
| -1% | -$1.56K | ﹤0.01% | 5556 |
|
|
2016
Q3 | $218K | Sell |
37,184
-3,773
| -9% | -$13.2K | ﹤0.01% | 4978 |
|
|
2016
Q2 | $123K | Buy |
40,957
+26,919
| +192% | +$111K | ﹤0.01% | 5157 |
|
|
2016
Q1 | $76K | Sell |
14,038
-130,896
| -90% | -$826K | ﹤0.01% | 5440 |
|
|
2015
Q4 | $1.72M | Sell |
144,934
-118,873
| -45% | -$1.36M | ﹤0.01% | 3629 |
|
|
2015
Q3 | $2.17M | Buy |
263,807
+252,489
| +2,231% | +$2.92M | ﹤0.01% | 3436 |
|
|
2015
Q2 | $158K | Buy |
11,318
+4,400
| +64% | +$80.7K | ﹤0.01% | 5362 |
|
|
2015
Q1 | $166K | Sell |
6,918
-4,146
| -37% | -$93.2K | ﹤0.01% | 5293 |
|
|
2014
Q4 | $182K | Sell |
11,064
-38,036
| -77% | -$439K | ﹤0.01% | 5294 |
|
|
2014
Q3 | $625K | Buy |
49,100
+40,661
| +482% | +$613K | ﹤0.01% | 4413 |
|
|
2014
Q2 | $190K | Sell |
8,439
-16,572
| -66% | -$300K | ﹤0.01% | 5184 |
|
|
2014
Q1 | $707K | Buy |
+25,011
| New | +$929K | ﹤0.01% | 4291 |
|
Other funds holding DRNA
Morgan Stanley's DRNA Position: Q4 2021 in Review
Morgan Stanley sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 1,736,277 shares — an estimated $35M sold.
Morgan Stanley first reported a position in DRNA in Q1 2014 and held it in 31 quarters. The position peaked at $41.5M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.
- Morgan Stanley reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
- Morgan Stanley sold 1,736,277 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $35M.
- Morgan Stanley first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2014 and held it in 31 quarters.
- Morgan Stanley's Dicerna Pharmaceuticals, Inc. position peaked at $41.5M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.
Based on Morgan Stanley's 13F filing for Q4 2021, filed 14 Feb 2022.